Every cell in your immune system uses cyclic AMP (cAMP) as a molecular brake pedal — a second messenger that dials down inflammatory activation and keeps immune responses proportionate. Adenylyl cyclase 7 (ADCY7) is the enzyme that produces cAMP in lymphocytes¹¹ lymphocytes
white blood cells that orchestrate adaptive immunity, myeloid cells, and thyroid epithelium. The rs78534766 variant swaps one amino acid in ADCY7 (aspartate 439 → glutamate) and cuts the enzyme's cAMP output by roughly 40% — loosening the brake on immune activation.

This is a rare variant. Only about 1 in 100 people of European descent carries even one copy. But when it does occur, the effect is large enough that it stands out in studies involving tens of thousands of people, ranking among the most significant non-HLA coding effects identified in autoimmune disease genetics.

The Mechanism

When ADCY7 carries the D439E substitution, the protein still reaches the cell membrane but produces substantially less cAMP in response to G protein-coupled receptor signals — including the TSH receptor²² TSH receptor
thyroid-stimulating hormone receptor, the primary driver of thyroid cell growth and function on thyroid epithelial cells and immune receptors on T cells and macrophages.

Without adequate cAMP signaling, immune cells shift toward a Th2 phenotype³³ Th2 phenotype
T-helper 2 pattern: characterised by interleukin-4, IL-5, and IL-13 production, which promotes allergic and certain autoimmune responses and simultaneously upregulate surface expression of MHC class II molecules and CD86 (a co-stimulatory signal). The combined effect — more antigen presentation, more co-stimulatory signal, Th2-polarised cytokine environment — creates conditions that favour inappropriate immune activation against self-antigens, including thyroid peroxidase and thyroglobulin.

The Evidence

The initial discovery came from a 2017 whole-genome sequencing study of 16,432 inflammatory bowel disease cases and 18,843 controls by Luo et al.: the ADCY7 missense variant (0.6% MAF) doubled ulcerative colitis risk⁴⁴ the ADCY7 missense variant (0.6% MAF) doubled ulcerative colitis risk and was the most significant non-HLA coding association in the dataset (OR ≈ 2.0–2.16; p = 1×10⁻¹⁴). The same variant has since been replicated in the GWAS Catalog with an OR of 2.16 [1.77–2.62] for ulcerative colitis across independent cohorts.

In parallel, thyroid disease GWAS studies identified the same variant. A 2024 autoimmune hypothyroidism GWAS by Reeve et al. lists ADCY7 among established coding variants with OR 1.46 for autoimmune thyroid disease⁵⁵ OR 1.46 for autoimmune thyroid disease (p = 1×10⁻¹⁴). The 2025 Nature Genetics GWAS by Rand et al. (113,393 hypothyroidism cases, 1,065,268 controls)⁶⁶ (113,393 hypothyroidism cases, 1,065,268 controls) — the largest hypothyroidism genetic study to date — independently confirms the ADCY7 locus at p = 1×10⁻¹⁶.

Mechanistic confirmation came from Cardinale et al. in 2025: cell-based experiments showed the D439E protein retains membrane localisation but produces 40% less cAMP⁷⁷ cell-based experiments showed the D439E protein retains membrane localisation but produces 40% less cAMP. ADCY7 knockdown in immune cells replicated the molecular phenotype — Th2 cytokine skewing and elevated MHC class II + CD86 — explaining the autoimmune predisposition. The authors proposed that enhancing cAMP production (by direct ADCY7 activation or phosphodiesterase inhibition) could be a therapeutic strategy.

Population data shows the A allele is absent in East Asian populations and very rare in African populations, with the highest frequency (~0.6%) in Europeans. Eosinophil counts are also elevated in carriers (GWAS effect 0.097 SD/allele), consistent with a Th2-shifted immune baseline.

Practical Actions

Carrying the A allele means your ADCY7 enzyme is operating at roughly 60% of its normal cAMP-generating capacity. This has two practical implications: (1) earlier and more regular thyroid screening is warranted, since the same immune dysregulation that raises ulcerative colitis risk also raises autoimmune thyroid disease risk; and (2) thyroid peroxidase antibody testing identifies autoimmune thyroid disease years before TSH levels shift.

Selenium has a specific, well-documented role in reducing thyroid peroxidase antibody titres in autoimmune thyroiditis. This is a genuinely genotype-relevant recommendation: the A allele creates an immune environment that promotes antibody-mediated thyroid attack, and selenium supplementation targets exactly that mechanism by supporting selenoprotein-based antioxidant defence in thyroid tissue.

If diagnosed with Hashimoto's thyroiditis or early hypothyroidism, monitoring the free T4/T3 ratio alongside TSH is useful — the GWAS data shows A allele carriers who receive levothyroxine treatment require larger dose adjustments (beta 0.45 dose units; GWAS Catalog GCST90042535), suggesting altered thyroid hormone sensitivity or clearance.

Interactions

The strongest interaction of interest is with other autoimmune loci. Carriers of the ADCY7 A allele who also carry risk variants at immune checkpoint genes (PTPN22 rs2476601, TYK2, IFIH1) face a compounded autoimmune predisposition. These interactions are not yet quantified in published compound heterozygosity studies, but the biological logic is clear — multiple immune regulatory defects are additive.

The ADCY7 variant also shares its cAMP-regulatory pathway with adenylyl cyclase isoforms expressed in the thyroid, suggesting potential interactions with TSH receptor signalling variants (e.g., rs4704397 in PDE8B, which regulates TSH-driven cAMP clearance). Whether carrying both variants additively impairs thyroid cAMP signalling awaits direct study.

The bronchial epithelium is the first line of defense against airborne pathogens, including the ubiquitous mould Aspergillus fumigatus¹¹ Aspergillus fumigatus
Aspergillus fumigatus is a common airborne fungus that causes little harm in healthy lungs but can colonize and invade in those with compromised barriers or suppressed immunity. ZNF77 — zinc finger protein 77 — is a transcription factor expressed in bronchial epithelial cells that helps regulate the structural proteins keeping the airway lining sealed. The rs35699176 variant creates a premature stop codon (Q100*) that truncates ZNF77 protein at position 100, eliminating most of its functional zinc-finger DNA-binding domains and compromising this regulatory role.

The Mechanism

ZNF77 is encoded on the minus strand of chromosome 19 (GRCh38 position 2,936,537). The variant is a G-to-A change on the plus strand, which corresponds to a C-to-T change in the coding sequence (c.298C>T), converting the glutamine codon (CAG) at position 100 to a stop codon (TAG) — hence the designation p.Gln100Ter.

Gago et al. 2018²² Gago et al. 2018
Gago S et al. Lung colonization by Aspergillus fumigatus is controlled by ZNF77. Nature Communications 9:3835 used genome-edited bronchial epithelial cells carrying rs35699176 to show that the truncated protein causes:

• Reduced transepithelial electrical resistance (p < 0.0001) — a direct measure of barrier tightness
• Elevated extracellular matrix (ECM) proteins on the cell surface
• Enhanced A. fumigatus conidial adhesion at 30 and 120 minutes post-exposure
• Faster conidial germination and greater hyphal extension
• Increased fungal cytotoxicity to the epithelial layer

RNA-seq and mass spectrometry (LC-MS/MS) revealed that the variant upregulates vesicle trafficking pathways, increasing secretion of ECM adhesion proteins that fungal conidia exploit as attachment anchors. The end result is a more permissive landing surface for Aspergillus.

The Evidence

The clinical arm of the Gago et al. study compared A. fumigatus airway loads in patients with fungal asthma stratified by rs35699176 genotype. Patients heterozygous for the variant (AG) had significantly higher airway fungal loads³³ Patients heterozygous for the variant (AG) had significantly higher airway fungal loads
Heterozygous rs35699176+/- patients with fungal asthma showed higher A. fumigatus loads compared to wild-type patients in the Gago 2018 clinical cohort than those carrying two wild-type G alleles. The authors proposed ZNF77 genotype as a potential "risk marker for patient stratification" in allergic bronchopulmonary aspergillosis (ABPA) and related fungal airway diseases.

A separate population study (Hallengren et al. 2015⁴⁴ Hallengren et al. 2015
Hallengren E et al. Analysis of Low Frequency Protein Truncating Stop-Codon Variants and Fasting Concentration of Growth Hormone. PLoS One 10(6)) identified the same variant in 5,451 individuals from the Malmö Diet and Cancer cohort and found a modest association with higher fasting growth hormone (β = 0.12 SD per minor allele, p = 0.02) and borderline taller stature. The authors considered this preliminary and requiring replication; the growth hormone finding has no direct relevance to fungal susceptibility.

The evidence base is currently a single well-mechanised study (Gago 2018) with in vitro and patient-cohort support but no independent replication, placing this variant firmly in the emerging evidence tier. No GWAS catalog entries or ClinVar classifications exist for this rsid.

Practical Actions

For carriers of the A allele — particularly those with asthma, structural lung disease, or who are immunosuppressed — the ZNF77 Q100* variant is a signal to take airway fungal exposure seriously. The bronchial epithelium is less able to exclude Aspergillus conidia, increasing the probability that inhaled spores establish meaningful colonization rather than being cleared.

Reducing environmental mould load and having a low threshold for investigating persistent respiratory symptoms are the most evidence-consistent responses. Spirometry and bronchial challenge testing can help characterise baseline airway function. In atopic individuals, serum IgE and Aspergillus-specific IgE (RAST) can quantify sensitisation.

Interactions

ZNF77 operates as a transcription factor upstream of structural epithelial proteins; interactions with other barrier-integrity loci (e.g., filaggrin FLG variants associated with atopic march) are biologically plausible but not yet studied for this specific variant. ABPA susceptibility also involves IL-4R, IL-13, and HLA-DR loci — gene-gene interaction data for rs35699176 with these variants does not yet exist in the literature.

One in three people experiences clinically significant motion sickness, yet the biological reasons have long been obscure. In 2015, Hromatka et al.¹¹ Hromatka et al.
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics published the first genome-wide association study of motion sickness in 80,494 individuals from 23andMe — and found 35 genome-wide-significant loci spanning inner-ear development, neurological processes, and, unexpectedly, glucose homeostasis. The second strongest signal in the entire study was rs56051278, located in an intron of GPD2 on chromosome 2 (P = 1.5×10⁻²⁹, beta = +0.066 per G allele).

The Mechanism

GPD2 encodes mitochondrial glycerol-3-phosphate dehydrogenase²² mitochondrial glycerol-3-phosphate dehydrogenase
a FAD-dependent enzyme on the inner mitochondrial membrane that oxidises glycerol-3-phosphate to dihydroxyacetone phosphate, transferring electrons into the mitochondrial electron transport chain and regenerating cytosolic NAD⁺ from NADH produced during glycolysis — a process called the glycerol phosphate shuttle. This shuttle is critical for sustaining glycolysis in tissues that rely on rapid glucose oxidation, including neurons and intestinal smooth muscle cells.

rs56051278 is an intronic variant, but it is in high linkage disequilibrium (r² ≈ 0.8)³³ high linkage disequilibrium (r² ≈ 0.8)
LD means these two variants are nearly always inherited together; rs56051278 likely serves as a tag for the functional missense change with rs2116665, a missense variant in GPD2 (R264H) previously associated with elevated free fatty acid and glycerol levels in plasma — biomarkers of impaired mitochondrial fatty acid oxidation and glucose intolerance. The GWAS signal at rs56051278 almost certainly reflects functional consequences of the nearby rs2116665 missense change.

The downstream physiology connects to the GI tract in a specific way: during vestibular stimulation, glucose regulation is perturbed. A dedicated experimental study by Mo et al. 2012⁴⁴ Mo et al. 2012
Acute hyperglycemia is related to gastrointestinal symptoms in motion sickness. Physiological Behavior found that individuals who developed nausea and vomiting during motion exposure had significantly lower pre-exposure insulin than those who did not (P<0.05), and that acute hyperglycemia — a consequence of insulin insufficiency — was greater in the symptomatic group. In a rat arm of the same study, pre-treating animals with insulin before acceleration significantly reduced the motion sickness index. The authors concluded that "stable glucose levels can help to relieve gastrointestinal symptoms in motion sickness." GPD2's role in sustaining neuronal and smooth-muscle glucose metabolism positions it as a plausible biological link between this genetic signal and the clinical phenotype.

The Evidence

The Hromatka GWAS enrolled 80,494 individuals of European ancestry drawn from the 23andMe cohort. Motion sickness susceptibility was self-reported using a validated questionnaire covering car, boat, and aeroplane sickness. rs56051278 reached P = 1.5×10⁻²⁹ with a beta of +0.066 per G allele (effect allele). This is a well-powered, well-replicated association — the sample size exceeds most GWAS of neurological phenotypes, and the signal at the GPD2 locus was among the top two genome-wide.

The paper further notes that several of the 35 hits, including rs56051278, "display sex-specific effects, with up to three times stronger effects in women" across the broader set. The glucose-homeostasis cluster of hits (also including variants near UBE2E2, GPR26, RGS5, and NR2F2) was highlighted as a biologically coherent group distinct from the inner-ear development loci.

Practical Actions

For G allele carriers, motion sickness susceptibility is partly driven by impaired mitochondrial glucose handling during vestibular stress. The actionable implication is pre-travel metabolic priming: eating a mixed carbohydrate meal 1–2 hours before travel, supplementing with ginger (which has direct anti-emetic evidence), and avoiding fasted states before or during motion exposure. These strategies stabilise the glucose fluctuations that the Mo 2012 study linked to GI symptom severity.

Interactions

rs56051278 is a tag SNP for the functional missense variant rs2116665 (R264H in GPD2) — the two are in high LD (r² ≈ 0.8) and should not be treated as independent associations. Future analysis comparing carriers of both to carriers of only one tag should be interpreted cautiously. The strongest hit in the same GWAS was rs66800491 near PVRL3 (a cell-adhesion molecule involved in inner ear development), which tags a completely distinct biological mechanism — inner-ear structural variation — with no expected interaction with the GPD2 glucose pathway.

Your kidneys filter about 700 mg of uric acid daily, reabsorbing most of it back into the bloodstream. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, also called GLUT9, a voltage-driven urate transporter expressed in the proximal tubule of the kidney that handles most renal urate reabsorption — the protein responsible for setting your urate "baseline." The rs6814664 C>T variant sits within an intron of SLC2A9 and does not change the protein itself, but tags a broader regulatory signal that modulates how much urate your kidneys return to the bloodstream.

This variant is part of a cluster of intronic SLC2A9 SNPs identified in genome-wide association studies as tagging the same biological signal: variation in GLUT9 transport efficiency. As a tag SNP, rs6814664 captures the urate association through linkage disequilibrium with functional variants elsewhere in the gene.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a (long form) located on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the blood, and GLUT9b (short form) on the apical membrane. Together they form a "urate-recapture" system: urate filtered from blood enters the tubular lumen, is reabsorbed by apical transporters including URAT1, and then re-enters the circulation via GLUT9a.

Intronic variants in SLC2A9 are thought to exert their effects through altered gene expression rather than protein structure changes. The SLC2A9 locus contains active enhancers in hepatic and erythroid cell types, and fine-mapping studies²² fine-mapping studies
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 identify epistatic interactions between intronic and intergenic variants that together explain about 6% of serum urate variance. The rs6814664 C allele likely tags regulatory haplotypes that drive higher GLUT9 expression or greater transport efficiency, resulting in more urate being returned to the blood.

The Evidence

Sex-specific effects are the defining feature of SLC2A9 intronic variants. The landmark KORA genome-wide scan by Döring et al.³³ Döring et al.
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 (n = 1,644 primary cohort plus three replication samples) showed that intronic SLC2A9 variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men but a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele copy, with women showing up to twice the effect size of men in replication cohorts. Separately, SLC2A9 isoform 2 expression was significantly associated with serum urate, explaining 3.5% of variance in men and 15% in women. This sex divergence likely reflects estrogen-mediated regulation of GLUT9 expression and the lower baseline urate levels in women, where relative changes are more detectable.

The SLC2A9 locus overall was characterised by Vitart et al.⁴⁴ Vitart et al.
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 as the single strongest genetic determinant of serum urate, with variants explaining 1.7–5.3% of urate variance across Croatian, UK, and German samples. Variants at this locus were also associated with reduced fractional excretion of uric acid (less urate in the urine), confirming that the mechanism is impaired renal excretion rather than overproduction.

BMI interaction: A study in the Bruneck and Utah cohorts⁵⁵ study in the Bruneck and Utah cohorts
Döring A et al. Sex-specific association of SLC2A9 variants with uric acid levels is modified by BMI. 2008 (n = 2,669) found that SLC2A9 intronic variant effects on serum urate are amplified in individuals with higher BMI, with significant interaction p-values of 0.023–0.035. This means that C-allele carriers who are also overweight or obese accumulate a greater urate burden than the genetic effect alone would predict.

Population variation: The C allele shows striking population stratification: ~90% in East Asians, ~57% in Europeans, ~32% in Africans. This gradient mirrors the known cross-ancestry differences in serum urate and gout prevalence — East Asian populations, who carry the highest C-allele burden at this locus, also have among the highest gout prevalence globally.

Practical Actions

Intronic SLC2A9 variants affect urate reabsorption efficiency. Dietary and metabolic levers that directly modulate the urate load reaching those transporters are the most tractable interventions.

The key dietary modulators of serum urate for C-allele carriers are: organ meats (liver, kidney, sweetbreads) and red meat, which supply large purine loads; alcohol — particularly beer and spirits, which elevate urate both through purine content and by competing with urate for renal excretion; and high-fructose beverages, since fructose catabolism generates inosine monophosphate (a direct urate precursor) and fructose itself competes with urate for tubular exchange via SLC2A9. Dairy and coffee are associated with modestly lower serum urate in epidemiological studies.

The crystalisation threshold for monosodium urate is 6.8 mg/dL at physiological temperature. Maintaining serum urate below 6.0 mg/dL is a widely used clinical target to prevent and dissolve crystals and suppress gout flares.

Interactions

With rs3733591 (SLC2A9 Arg265His): rs3733591 is the larger-effect coding variant at SLC2A9, with the C allele adding ~0.65 mg/dL per copy in some studies. rs6814664 tags an independent intronic signal. Individuals carrying C alleles at both loci accumulate risk from two mechanistically distinct SLC2A9 sources — both should be examined to estimate total SLC2A9-attributed urate load.

With rs11942223 (SLC2A9 intronic, independent signal): rs11942223 is a second independent intronic SLC2A9 signal (LD with rs6814664 is partial but not complete). Carriers of risk alleles at both intronic loci have additive urate elevation and should consider more aggressive dietary restriction of fructose and purines.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. C-allele carriers at rs6814664 who also carry the ABCG2 Q141K T allele face urate accumulation from two independent routes — impaired renal clearance and impaired gut excretion — substantially increasing gout risk.

With BMI: The interaction between SLC2A9 genotype and BMI is one of the better-replicated gene-environment interactions for serum urate. CC homozygotes who are overweight or obese face compounded risk beyond what either factor predicts alone; weight management has outsized benefit in this group.

BTBD9 encodes a BTB/POZ domain-containing protein¹¹ BTB/POZ domain-containing protein
A protein scaffold that bridges substrates to the CUL3-RBX1 E3 ubiquitin ligase complex, marking target proteins for proteasomal degradation that controls how quickly certain proteins are cleared from cells. In the brain, BTBD9 appears to regulate iron homeostasis in dopaminergic pathways — the same system responsible for dopamine signalling in motor circuits and the rest-activity cycle. This makes BTBD9 the molecular bridge between two seemingly unrelated complaints: difficulty falling asleep, and an irresistible urge to move the legs at rest.

The rs9394502 variant sits in an intron of BTBD9 and acts as a tag SNP²² tag SNP
A marker in strong linkage disequilibrium with one or more functional variants; it travels with the causal allele through generations even if it isn't causal itself for the risk haplotype. People carrying one or two T alleles show measurably higher rates of insomnia and restless legs syndrome in some of the largest genetic studies ever conducted.

The Mechanism

BTBD9 functions as a substrate adaptor for the CUL3-based E3 ubiquitin ligase complex, targeting specific proteins for proteasomal degradation. In Drosophila, loss-of-function models of the BTBD9 homologue produce periodic leg movements and reduced dopamine levels — the core features of RLS — suggesting the protein controls dopamine turnover in motor circuits.

The iron connection is direct: iron is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. BTBD9 polymorphisms are significantly associated with serum ferritin levels in population studies, indicating that the protein influences systemic iron storage or turnover. When BTBD9 function is perturbed, iron homeostasis shifts, dopamine synthesis capacity falls, and the sensorimotor circuits controlling limb movements at rest become dysregulated — producing the classic RLS symptoms that are worst at night, when dopamine levels naturally dip to their daily minimum.

Insomnia and RLS share this biological substrate: both worsen when brain iron is low, both respond to iron repletion when ferritin is deficient, and both are enriched among carriers of BTBD9 risk variants.

The Evidence

The insomnia association was established at genome-wide significance by Jansen et al. 2019³³ Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet, 2019;51:394-403. In 1,331,010 individuals — one of the largest psychiatric GWAS at the time — rs9394502 reached p=8×10⁻¹⁸ with an odds ratio of 1.056 (95% CI 1.04–1.07). The modest per-allele effect size (5.6% increased odds per T allele) is typical for common polygenic risk variants; the significance is extraordinary because the sample is enormous.

The finding was independently replicated by Watanabe et al. 2022⁴⁴ Watanabe et al. 2022
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet, 2022;54:1125-1132 in an even larger meta-analysis (593,724 cases, 1,771,286 controls), where rs9394502 surpassed p=4×10⁻²⁰ — five orders of magnitude below the genome-wide significance threshold.

BTBD9's role in restless legs syndrome was established earlier. Winkelmann et al. 2007⁵⁵ Winkelmann et al. 2007
Winkelmann J et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet, 2007;39:1000-6 reported BTBD9 as one of three genome-wide significant RLS loci, with each risk variant conferring more than 50% increased risk for RLS. Subsequent studies confirmed that BTBD9 risk alleles also associate with periodic limb movements of sleep (PLMS), a closely related motor phenotype that disrupts sleep architecture even when the person is unaware of it.

Practical Actions

For T allele carriers — particularly TT homozygotes — the most directly actionable intervention is iron status assessment. Clinical guidelines for RLS recommend checking serum ferritin and targeting levels above 75 ng/mL (some guidelines recommend 100 ng/mL) because brain iron deficiency drives symptoms even when hemoglobin is normal. This is a genotype-specific monitoring threshold: the general population guideline for iron deficiency (ferritin <12 ng/mL) dramatically underestimates the brain iron requirement in susceptible individuals.

For TT carriers with confirmed RLS, oral ferrous sulfate (325 mg every other day on an empty stomach) is the standard first-line approach when ferritin is below 75 ng/mL. For those who cannot tolerate oral iron or have malabsorption, intravenous ferric carboxymaltose produces faster and more sustained ferritin rises.

Interactions

The BTBD9 risk haplotype shows strongest effect when combined with other RLS-associated variants. rs3923809 (also in BTBD9) is in partial linkage disequilibrium with rs9394502; carriers of both risk alleles show stronger periodic limb movement severity. MEIS1 rs2300478 on chromosome 2p encodes a transcription factor in the same developmental pathway as BTBD9 and independently triples RLS risk — combined MEIS1 + BTBD9 risk genotypes are found in a substantial fraction of diagnosed RLS patients. MAP2K5 rs6494696 represents a third independent RLS locus identified in the same 2007 GWAS. Each locus acts additively; the compound risk from multiple BTBD9 + MEIS1 + MAP2K5 risk genotypes is an active area of research and a natural candidate for compound action entries.

When the GABRIEL Consortium published the largest asthma genome-wide association study of its era in 2010, one of the five genome-wide significant signals landed squarely on chromosome 2q12 — a dense cluster of interleukin-1 receptor family genes including IL1RL1 (ST2)¹¹ IL1RL1 (ST2)
The receptor for IL-33; encodes the ST2 protein that triggers type 2 immune responses when bound by the alarmin cytokine IL-33 and IL18R1²² IL18R1
Encodes the IL-18 receptor subunit 1, which partners with IL18RAP to form the functional IL-18 receptor complex. rs3771166 is the lead tag SNP for this locus, sitting within an intron of IL18R1 approximately 17 kb downstream of IL1RL1.

The Mechanism

rs3771166 is an intronic variant in IL18R1 that acts as a tag for regulatory variation across the entire IL1RL1/IL18R1/IL18RAP gene cluster. The 2q12.1 locus is a tightly packed receptor family cluster in which multiple variants are in partial linkage disequilibrium with one another. The G risk allele at rs3771166 captures the cumulative regulatory signal affecting expression of both IL18R1 (the IL-18 receptor) and nearby IL1RL1 (the IL-33 receptor / ST2). IL-18 and IL-33 are distinct but complementary alarmins³³ alarmins
Damage-associated cytokines released by stressed or dying epithelial cells; they activate innate immune sentinels without requiring pathogen-specific recognition that coordinate early type 2 immune activation. IL-18 can promote both Th1 responses (with IL-12) and amplify Th2/ILC2 responses (without IL-12), making IL18R1 expression a context-dependent modulator of airway inflammation magnitude.

The Evidence

Moffatt et al. (NEJM, 2010)⁴⁴ Moffatt et al. (NEJM, 2010)
A large-scale, consortium-based genomewide association study of asthma. NEJM 363:1211–1221 established rs3771166 as the lead signal at 2q12 with p=3×10⁻⁹ in 10,365 asthma cases and 16,110 controls, making it one of only five loci to reach genome-wide significance in what was then the largest asthma GWAS. The G allele confers an odds ratio of approximately 1.15 per copy (95% CI 1.10–1.20), placing it in the moderate-effect range typical of complex disease susceptibility variants.

The finding replicated across ancestry groups. Torgerson et al. (Nature Genetics, 2011)⁵⁵ Torgerson et al. (Nature Genetics, 2011)
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations confirmed the IL1RL1 locus in European American, African American, and Latino cohorts, demonstrating that this signal is not population-specific. Wan et al. (Thorax, 2012)⁶⁶ Wan et al. (Thorax, 2012)
Genome-wide association study to identify genetic determinants of severe asthma extended the finding to severe asthma specifically, with the 2q12 locus achieving p=5.59×10⁻⁸.

Savenije et al. (JACI, 2014)⁷⁷ Savenije et al. (JACI, 2014)
Association of IL33-IL1RL1 pathway polymorphisms with wheezing phenotypes in childhood showed that different variants within this locus associate with distinct wheezing trajectories in birth cohorts — late-onset wheeze maps specifically to IL1RL1 variants, highlighting how functional heterogeneity within the cluster shapes disease phenotype.

Practical Actions

The G allele at rs3771166 modestly elevates asthma and atopic airway disease risk, operating through the shared IL-18R/ST2 signaling axis. While rs3771166 itself is a tag SNP (its effect is attributed to regulatory changes across the locus rather than a direct protein change), the downstream consequences are identical to other variants in the cluster: reduced threshold for IL-33- and IL-18-driven type 2 airway inflammation.

G risk allele carriers benefit from early-warning monitoring of eosinophil counts, which reflect active type 2 inflammation through this pathway. For AG heterozygotes, standard monitoring suffices. For GG homozygotes — who carry the full additive genetic load at this locus — proactive lung function surveillance and early escalation of asthma treatment are well-supported by the evidence.

Interactions

rs3771166 is part of the same chromosomal locus as rs1420101 (the primary IL1RL1 eQTL for sST2 decoy receptor levels). These SNPs tag partially overlapping but potentially independent signals within the 2q12.1 cluster. Carrying risk alleles at both rs3771166 and rs1420101 may confer additive susceptibility, as each tags different functional elements within the IL1RL1/IL18R1/IL18RAP regulatory architecture.

The upstream IL33 gene variants rs992969 and rs1342326 are pathway partners: they increase IL-33 ligand production, which must then be buffered by the ST2/sST2 system partly regulated by this locus. Individuals with risk alleles across multiple nodes of the IL-33/ST2 axis (ligand, receptor, decoy) accumulate additive susceptibility.

CYP3A4 is the most important drug-metabolizing enzyme in the human body, responsible for the first-pass and systemic clearance of approximately 50% of all prescribed medications. When you swallow a statin, an immunosuppressant, or a benzodiazepine, CYP3A4 in your liver and intestinal wall is the primary enzyme that breaks it down before it reaches your bloodstream. A genetic variant that impairs this enzyme — even modestly — can therefore have significant consequences for how drugs behave in your body.

rs55785340, also known as CYP3A4*2, is a missense variant¹¹ missense variant
A mutation that changes a single amino acid in the protein sequence that substitutes proline for serine at position 222 of the CYP3A4 protein (p.Ser222Pro). It is rare globally — found almost exclusively in Europeans at an allele frequency of roughly 0.07% in large population databases — but its functional impact on nifedipine metabolism is well-documented in vitro, and a large pharmacokinetic study has now confirmed its clinical relevance for statin dosing.

The Mechanism

CYP3A4 catalyzes oxidative reactions by threading drug molecules into its active site, where an oxygen atom is transferred. Serine 222 sits in a substrate-recognition region of the enzyme. The Ser222Pro substitution replaces a flexible serine residue with a rigid proline, which is known to restrict backbone flexibility and alter local protein conformation. The resulting structural change affects how well the enzyme binds and processes certain substrates.

The original characterization by Sata et al. (2000)²² Sata et al. (2000)
Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12. Clin Pharmacol Ther 67:48-56 expressed the CYP3A4*2 enzyme in baculovirus and directly measured catalytic activity. The key finding was substrate-dependent impairment³³ substrate-dependent impairment
The CYP3A4*2 variant is a partial loss-of-function, not a complete null — its effect differs depending on which drug enters the active site: nifedipine oxidation showed reduced intrinsic clearance compared to wild-type, while testosterone 6β-hydroxylation was not significantly different. This substrate selectivity matters clinically because it means some CYP3A4 drugs are more affected than others.

The Evidence

The most clinically relevant evidence comes from a genomewide association study of simvastatin pharmacokinetics⁴⁴ genomewide association study of simvastatin pharmacokinetics
Mykkänen AJH et al. Genomewide Association Study of Simvastatin Pharmacokinetics. Clin Pharmacol Ther 2022;112(3):676-686 in 229 Finnish volunteers. Carriers of CYP3A4*2 or CYP3A4*22 (the more common *22 splice variant) showed 87% (90% CI, 39–152%) larger simvastatin acid AUC⁵⁵ AUC
Area under the concentration-time curve, the standard pharmacokinetic measure of total drug exposure than normal metabolizers (P=6.4×10⁻⁴). Because the study grouped *2 and *22 carriers together as "intermediate CYP3A4 metabolizers," the effect size specifically attributable to *2 is not isolated, but the direction is clear: heterozygous carriers are exposed to substantially more simvastatin acid per dose.

The mechanism explains this finding: simvastatin (as the acid form) is a CYP3A4 substrate, and with reduced enzyme activity, less drug is cleared on first pass through the intestinal wall and liver. The result is higher plasma concentrations per dose — the same pharmacokinetic principle that underlies the dangerous interactions between statins and CYP3A4 inhibitors like clarithromycin or grapefruit juice.

Population data from ExAC and 1000 Genomes⁶⁶ ExAC and 1000 Genomes
Large-scale sequencing consortia aggregating hundreds of thousands of samples confirms the variant is nearly absent outside European populations. Of 121,010 alleles in ExAC, only 104 carried the G allele (0.086%), and all occurrences were in non-African, non-East-Asian participants. The FINRISK Finnish cohort showed a slightly higher rate (~1%), consistent with population-specific enrichment in Northern Europe.

Practical Actions

For carriers of CYP3A4*2, the most directly actionable implication is statin safety. Statins metabolized by CYP3A4 — primarily simvastatin, lovastatin, and atorvastatin — will reach higher plasma concentrations per dose. High statin exposure raises the risk of myopathy and rhabdomyolysis⁷⁷ myopathy and rhabdomyolysis
Muscle inflammation and, in severe cases, breakdown of muscle tissue that can cause kidney failure (1-in-10,000 risk with standard doses). Pravastatin, rosuvastatin, and fluvastatin are largely independent of CYP3A4 and are not affected by this variant.

For immunosuppressants (tacrolimus, cyclosporine) after organ transplantation, reduced CYP3A4 activity would theoretically raise drug exposure and increase toxicity risk. However, because CYP3A4*2 is so rare, clinical guidelines have not been developed for it specifically — clinicians rely on therapeutic drug monitoring as standard of care for these drugs regardless of genotype.

There are currently no CPIC or DPWG guidelines specific to CYP3A4*2. Clinical pharmacogenomics testing panels that include CYP3A4 most commonly genotype for CYP3A4*22 (rs35599367) and CYP3A5*3 (rs776746), which are far more common and have established clinical utility. CYP3A4*2 is too rare for population-level clinical guidelines, but individual carriers benefit from genotype-aware prescribing.

Interactions

CYP3A4*2 can combine with CYP3A4*22 (rs35599367) or CYP3A5*3 (rs776746) on the other allele, producing compound genotypes with potentially greater reduction in total CYP3A enzyme activity. In a compound heterozygote carrying both CYP3A4*2 and CYP3A4*22 (one on each chromosome), overall CYP3A4 activity would be reduced from both alleles, yielding a predicted poor metabolizer phenotype for nifedipine- class substrates. This combination, while rare, would warrant extra caution with CYP3A4 substrates.

Environmental CYP3A4 inhibitors dramatically amplify the effect: grapefruit juice, clarithromycin, ketoconazole, and ritonavir can inhibit CYP3A4 by 3- to 8-fold. For a CYP3A4*2 carrier who already has baseline reduced clearance, adding a strong inhibitor compounds the exposure increase and significantly raises toxicity risk with narrow-therapeutic-index drugs.

Every time you form a new memory, a precise choreography of ion channels must activate in hippocampal neurons at the right moment. The CaV3.2 channel¹¹ CaV3.2 channel
T-type voltage-gated calcium channel encoded by CACNA1H; opens near the resting membrane potential, earning the "T" for transient and tiny currents is one of the key players in this process. Unlike the high-voltage-activated L-type channels that require strong depolarisation, T-type channels open with small, subthreshold voltage changes — making them ideally positioned to respond to weak synaptic inputs and gate whether those inputs are converted into durable synaptic changes. rs61734410 substitutes leucine for proline at position 640 in this channel, a region critical for channel gating. The change does not dramatically alter baseline channel function but reduces how the channel responds to certain modulating inputs, including pharmacological ones.

The Mechanism

Pro640 lies within the second intracellular loop of the CaV3.2 alpha-1H subunit, a domain involved in channel inactivation kinetics. The Pro640Leu substitution²² Pro640Leu substitution
proline is a structurally rigid amino acid that creates kinks in protein loops; replacing it with leucine, a flexible aliphatic residue, alters the loop's geometry and potentially the conformational transitions that control channel gating does not produce measurable differences in baseline CaV3.2 electrophysiology under standard conditions — current amplitude, activation voltage, and steady-state inactivation are unchanged. The variant's effect becomes detectable only when the channel is challenged: ethosuximide's ability to accelerate CaV3.2 inactivation (its core anti-epileptic mechanism) is significantly blunted for the Leu640 channel compared to wild-type Pro640.

Beyond pharmacodynamics, CaV3.2's role in cognition is well established at the channel level. CaV3.2 knockout mice show shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls³³ shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls
Chen et al. 2012, PLoS One; LTP = long-term potentiation, the cellular correlate of memory formation; shorter LTP means synaptic changes are less durable and impaired retrieval of context-associated memory without deficits in spatial learning. A separate study documented that CaV3.2-deficient mice fail novel object and spatial object recognition tasks with high statistical significance ⁴⁴ Gangarossa et al. 2014, Frontiers in Behavioral Neuroscience; novel object recognition p<0.001 compared to wild-type controls.

T-type calcium channels at synapses contribute to plasticity through a distinct mechanism: they activate at subthreshold potentials, driving calcium influx that can interact cooperatively with NMDA receptor signalling to lower the threshold for LTP induction. Nicholson & Kullmann 2017⁵⁵ Nicholson & Kullmann 2017
Journal of Physiology; demonstrated T-type channel- dependent, NMDA receptor-independent LTP in hippocampal interneurons showed that blocking T-type channels prevents LTP even when the standard NMDA receptor-dependent pathway is intact, establishing T-type channels as an independent gateway to synaptic strengthening.

The Evidence

Direct evidence for Pro640Leu and cognitive outcomes is limited — the variant has not been individually studied in human cognitive GWAS datasets at genome-wide significance. The biological evidence rests on the channel-level studies above and a pharmacogenetics finding: in a childhood absence epilepsy cohort, the Pro640Leu genotype was associated with higher odds of failing to achieve seizure-freedom on ethosuximide ⁶⁶ Glauser et al. 2017, Annals of Neurology; OR 2.63; n=81 patients; in vitro electrophysiology confirmed blunted drug effect at Leu640 channel. A separate replication study found no significant association in a smaller cohort (n=62), highlighting the moderate and still-contested nature of this pharmacogenetic claim.

At the population level, a case-control study ⁷⁷ Wang et al. 2024, Molecular Genetics & Genomic Medicine; 226 migraineurs vs 452 controls; ORadj 1.56, 95% CI 1.07-2.28 for CT genotype found the heterozygous CT genotype to be associated with migraine risk, consistent with CaV3.2's role in trigeminovascular pain signalling and cortical excitability. The ClinVar classification of this variant is Benign (multiple submitters, no conflicts), reflecting that it does not cause monogenic disease — the associations are probabilistic and polygenic.

Practical Actions

For CT and TT carriers, the most evidence-based intervention addresses the channel's known modulation by divalent cations. Magnesium is a natural blocker of T-type calcium channels — it competes with calcium at the channel pore and modulates gating through surface charge screening. This is the same class of action that gives magnesium its anti-migraine benefit in clinical trials. Supplementing magnesium glycinate or threonate supports this channel-level modulation while also providing general neurological benefits through NMDA receptor regulation.

DHA (docosahexaenoic acid) incorporates into neuronal membrane phospholipids and maintains the membrane fluidity required for optimal ion channel conformational dynamics. Membranes depleted in DHA are more rigid, altering the voltage- sensing properties of embedded channels including T-type calcium channels. For TT carriers facing the greatest Leu640 channel dosage, ensuring adequate DHA intake supports the membrane environment in which CaV3.2 operates.

If you or a family member carry this variant and are being treated for childhood absence epilepsy with ethosuximide, the pharmacogenetics data provide a rationale for discussing alternative or adjunctive agents with a neurologist, as the Leu640 channel shows reduced pharmacodynamic sensitivity to ethosuximide's mechanism.

Interactions

CaV3.2 operates in concert with the broader T-type channel family: CaV3.1 (CACNA1G) and CaV3.3 (CACNA1I) are expressed in overlapping brain regions and can partially compensate for CaV3.2 deficiency in some circuits. Variants in CACNA1A (rs10405121), which encodes the P/Q-type CaV2.1 channel dominant in cerebellar and cortical neurons, represent a distinct calcium channel pathway but converge on similar migraine and neurocognitive phenotypes. The migraine risk from rs61734410 is expected to be additive with TRPM8 locus risk (rs10166942), which operates through a separate cold-pain threshold mechanism.

Your kidneys filter roughly 700 mg of uric acid per day, and the dominant genetic determinant of how efficiently they do so is the SLC2A9 gene. Most people have heard of gout as a dietary problem — too much red meat, too much beer — and diet does matter. But for individuals carrying risk variants at SLC2A9, the kidneys are genetically programmed to reabsorb more urate back into the bloodstream than they should, regardless of diet.

rs6815001 is an [intronic variant | a variant in the non-coding region within a gene, which typically influences gene expression, splicing, or regulatory element function rather than directly changing the protein sequence] within SLC2A9 that tags an independently acting haplotype affecting renal urate clearance. It is a statistically independent signal from the well-characterized Arg265His missense variant (rs3733591), meaning that it captures different genetic architecture at this locus — distinct combinations of regulatory variants in linkage disequilibrium that influence how much GLUT9 is expressed or how the two protein isoforms are balanced.

The Mechanism

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate with far higher affinity than glucose in the kidney proximal tubule, the major renal urate transporter. GLUT9 exists in two isoforms: the long isoform (GLUT9a) localizes to the basolateral membrane of proximal tubule cells and mediates urate reabsorption from the tubular interstitium back into the bloodstream; the short isoform (GLUT9b) sits on the apical membrane and handles secretion into the tubular lumen. The net balance of these two activities determines how much urate your kidneys retain versus excrete.

Intronic variants in SLC2A9 like rs6815001 influence urate levels through regulatory mechanisms — altering transcription factor binding, changing the ratio of GLUT9a to GLUT9b expression, or modifying splice site usage. Fine-mapping studies of the SLC2A9 locus have identified at least five independent marginal effects and three epistatic SNP pairs in the 4p16.1 region (Wei et al., 2014)²² (Wei et al., 2014), with the rs6815001 haplotype representing one of these statistically separable signals. The G allele at rs6815001 tags a haplotype associated with less efficient net urate excretion, while the C allele tags a haplotype that supports more favorable urate clearance.

The fructose connection adds another dimension: GLUT9 also transports fructose, and fructose metabolism generates urate through AMP catabolism. High fructose intake therefore amplifies the effect of G-allele haplotypes, because both dietary urate precursors and impaired renal clearance push serum urate upward simultaneously.

The Evidence

SLC2A9 as the dominant urate locus: The SLC2A9 locus was first identified as a urate determinant in 2008 through parallel GWAS in Croatian and German populations, with intronic variants accounting for 1.7–5.3% of serum uric acid variance — the largest single-locus effect known for a quantitative trait in humans (Vitart et al., 2008)³³ (Vitart et al., 2008).

Multiple independent signals at SLC2A9: Conditional analysis consistently reveals that a single lead SNP does not capture all the genetic information at this locus. In African-ancestry populations, conditional analysis identified a second independent signal (p = 5.75 × 10⁻¹⁷ after conditioning on the primary signal), demonstrating that multiple causal or tagging variants act through separable mechanisms (Chen et al., 2020)⁴⁴ (Chen et al., 2020). Regional fine-mapping of 4p16.1 found five independent marginal effects plus epistatic interactions between SNP pairs, together explaining 1.5% more urate variance than the lead SNP alone (Wei et al., 2014)⁵⁵ (Wei et al., 2014).

Sex-specific amplification: SLC2A9 variants overall have disproportionately larger effects in women than in men: they explain 3.4–8.8% of urate variance in women versus 0.5–2.0% in men (Dalbeth et al., 2015)⁶⁶ (Dalbeth et al., 2015). Estrogen independently promotes renal urate excretion, so pre-menopausal women carrying risk alleles may have partially attenuated effects. Post-menopausal women lose this buffering and become more vulnerable to genetically elevated uric acid.

Metabolic syndrome amplification: Insulin resistance independently impairs renal urate excretion. Individuals carrying SLC2A9 risk haplotypes and also having metabolic syndrome experience substantially higher gout risk (OR ~1.39) compared to those with genetic risk alone, establishing a gene-environment interaction that makes metabolic health a key modifiable target for SLC2A9 risk carriers.

Practical Actions

The G allele at rs6815001 tags a haplotype that contributes to elevated serum uric acid through impaired renal clearance. Since this is a regulatory effect (not a missense change in the transporter itself), the magnitude is expected to be smaller per allele than the Arg265His missense variant, but it compounds when both signals are unfavorable. Dietary and lifestyle changes that support renal urate excretion are the evidence-based first line.

The uric acid threshold that matters is 6.8 mg/dL — this is the saturation point for monosodium urate crystal formation in synovial fluid at body temperature. Keeping serum urate below 6 mg/dL provides a meaningful safety margin. Dietary purines (organ meats, red meat, shellfish), alcohol (especially beer), and fructose-sweetened beverages each raise serum urate by 0.3–1.0 mg/dL and are modifiable targets. Conversely, low-fat dairy, coffee, and vitamin C have evidence for modest uric acid reduction and can serve as genotype-aware substitutions.

Interactions

rs6815001 and rs3733591 (Arg265His): These two SLC2A9 variants are statistically independent (low linkage disequilibrium), meaning a person can carry risk alleles at both simultaneously. Individuals who carry the G allele at rs6815001 and the C allele at rs3733591 carry additive risk from two distinct SLC2A9 mechanisms — one regulatory (rs6815001) and one functional/missense (rs3733591). The combination should be considered when counseling about gout prevention intensity.

rs6815001 and ABCG2 rs2231142: ABCG2 mediates intestinal urate secretion while SLC2A9 mediates renal reabsorption — independent pathways. Risk alleles at both loci produce additive serum urate elevation substantially greater than either alone, and in combination with metabolic syndrome push mean uric acid well above the hyperuricemia threshold even in otherwise healthy adults.

Fructose and sugar-sweetened beverages: High fructose intake generates urate through AMP catabolism and also competes with urate for renal excretion. For G-allele carriers already dealing with impaired renal clearance, high fructose intake provides a second independent driver of urate accumulation, making fructose reduction a particularly high-yield dietary target.

PEMT (phosphatidylethanolamine N-methyltransferase) is an enzyme in the liver that produces phosphatidylcholine ¹¹ A major component of cell membranes and bile, essential for fat transport from the liver (PC) from phosphatidylethanolamine using three sequential methylation reactions. Phosphatidylcholine is a critical component of cell membranes, bile (needed for fat digestion), and VLDL particles (which transport fat from the liver). PEMT is the body's primary internal source of choline, reducing dependence on dietary intake.

The Mechanism

The Val175Met variant ²² Valine-to-methionine substitution at position 175 of the protein (p.Val175Met) (rs7946) substitutes valine with methionine at position 175 of the PEMT protein. The T allele (Met) reduces enzyme activity by approximately 30%, meaning less phosphatidylcholine is produced internally. This shifts the burden to dietary choline sources. Each methylation reaction requires one S-adenosylmethionine (SAM) ³³ SAM is the body's universal methyl donor molecule, so PEMT activity is also dependent on overall methylation capacity. Notably, the T allele is very common in Europeans (75% frequency) but much rarer in East Asians (24%).

The Gender Dimension

PEMT is an estrogen-responsive gene — estrogen upregulates its expression. This means premenopausal women with PEMT variants may be partially protected by their estrogen levels. However, postmenopausal women with PEMT variants face a particularly high risk of choline deficiency because they lose both the genetic capacity and the hormonal support for internal choline production.

The Evidence

A clinical trial at UNC Chapel Hill⁴⁴ A clinical trial at UNC Chapel Hill
da Costa KA et al. FASEB J 2006 — common genetic polymorphisms affect the human requirement for the nutrient choline demonstrated that women with PEMT variants who consumed a low-choline diet developed liver dysfunction (fatty liver, elevated liver enzymes) significantly more often than women without the variant. A Japanese study⁵⁵ Japanese study
Song J et al. PEMT Val175Met and NASH susceptibility, 2007 confirmed that the variant is significantly more frequent in NASH patients. More recent research shows sex-specific effects⁶⁶ sex-specific effects
PEMT rs7946 polymorphism and sex modify choline effect on hepatic steatosis risk, 2023 where adequate dietary choline intake modifies the risk of hepatic steatosis differently in men and women.

Practical Implications

Egg yolks are the most practical dietary source of choline (about 150mg per yolk). Liver is even richer but less commonly consumed. If you carry the T allele, deliberately including choline-rich foods daily is one of the simplest and most impactful dietary strategies informed by your genetics. This is especially important if you also have MTHFD1 variants (rs2236225), which independently increase choline needs.

Interactions

PEMT interacts with MTHFD1 (rs2236225) — both variants increase choline requirements, and the combined effect can be substantial. It also interacts with MTHFR (rs1801133), as PEMT activity depends on SAM from the methylation cycle.